Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 65-69

  Witjes, Wim P J ^a,b   Schulman, Claude C ^a   Debruyne, Frans M J ^a  

^a ERASME HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GOSERELIN;

CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FLUTAMIDE; GOSERELIN; HUMANS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0030982859     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00171-4     Document Type: Conference Paper

References (14)

1. Huggins C, and Hodges CV: Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
2. Witjes WPJ, Oosterhof GON, Schaafsma HE, and Debruyne FMJ: Current status of neoadjuvant therapy in localized prostate cancer. Prostate 27: 297-303, 1995.
3. Oesterling JE, Andrews PE, Suman VJ, Zincke H, and Myers RP: Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149: 779-782, 1993.
4. Fair WR, Aprikian A, Sogani P, Reuter V, and Whitmore WF: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71: 1031-1038, 1993.
5. Hermanek P, and Sobin LH: TNM Classification of Malignant Tumors: International Union Against Cancer, 4th ed. Heidelberg, Springer, 1987.
6. Têtu B, Labrie F, Dupont A, and Monfette G: Histopathological effect of combination therapy on normal prostate and prostatic adenocarcinoma, in Labrie F, Lee F, and Dupont A: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. Amsterdam, Elsevier Science Publishers, 1989, pp 63-75.
7. Wojno KJ, and Epstein JI: The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 19: 251-260, 1995.
8. Edelstein RA, Zietman AL, De la Morenas A, Krane RJ, Babayan RK, Dallow KC, Traish A, and Moreland RB: Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 47: 370-375, 1996.
9. MacFarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, and deKernion JB: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 150: 132-134, 1993.
10. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, and Puraz Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154: 424-428, 1995.
11. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, and Baert L: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margin in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154: 429-434, 1995.
12. Schulman CC: Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate 5: 9-14, 1994.
13. Labrie F, DuPont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, LeMay M, Têtu B, Emond J, Candas B: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16: 499-509, 1994.
14. Goldenberg SL, Klotz LM, Srigley J, Jewett MAS, Mador D, Fradet Y, Barkin J, Chin J, Faquin J, Bullock MJ, Laplante S, and Canadian Urologic Group: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 165: 873-877, 1996.